Ratiopharm’s owner called a news conference for 1300 GMT to address the sale of the German generic drugs maker, after a three-way race that could trigger the richest takeover of a copycat drugmaker in nearly two years. One source close to the deal says a buyer has been picked, but declined to give any more details.
JPMorgan has lost a court dispute over fees relating to a client’s $1.2 billion Australian takeover defence. An Australian court dismissed the bank’s claim for millions in fees from Consolidated Minerals, which was taken over by Ukrainian billionaire Gennadiy Bogolyubov’s Palmary Enterprises in 2008. Read the Reuters story here.
And the UK press widely questions whether Prudential boss Tidjane Thiam should have taken on a role on the board of French bank Societe Generale, given that he has just launched a $35.5 billion takeover bid for AIG’s Asian life insurance business. He’s got enough on his plate, they say, with the need to convince investors to buy in to a $21 billion rights issue.
For all other Reuters stories on deals, click here. Elsewhere in media (some links may require subscription):
Liberty Media Corp and hedge fund Elliott Management Corp have decided not to bid for Hollywood studio Metro-Goldwyn-Mayer Inc, Bloomberg says.
ArcelorMittal, the world’s largest steelmaker, is in talks to buy a stake in unlisted Indian steel producer Bhushan Power & Steel Ltd to gain access to its plant and mining rights, according to the Economic Times.
Sweden’s Ericsson will buy a controlling stake in a joint venture between South Korea’s LG Electronics and Nortel Networks Corp, the Seoul Economic Daily’s Web service reports.
Private equity firm Apax Partners has been talking with Polycom Inc to take the U.S. video conferencing company private for more than $3 billion, the Financial Times says.
WestLB’s real estate finance unit is attracting interest from private equity houses Blackstone, Apollo and Colony, the Financial Times Deutschland reports.
The global market for initial public offerings is showing new signs of life after a spate of downsizings and postponements. Issue prices are not always what companies originally hoped for, however, and investors are being selective.